A review on the use of statins and tocotrienols, individually or in combination for the treatment of osteoporosis

Current Drug Targets

Volumn 14, Issue 13, 2013, Pages 1579-1590

  Abdul Majeed, Saif ^a   Mohamed, Norazlina ^a   Soelaiman, Ima Nirwana ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Combination; HMGCoA reductase; Individaul; Mevlonate; Osteoporosis; Statins; Tocotrienols

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CERIVASTATIN; DELTA TOCOTRIENOL; DENOSUMAB; ESTROGEN; GAMMA TOCOTRIENOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NITRILOTRIACETATE IRON; PARATHYROID HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIMVASTATIN; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; VITAMIN D;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BMP 2 GENE; BONE DENSITY; BONE DEVELOPMENT; BONE INJURY; BONE MASS; BONE METABOLISM; BONE NECROSIS; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG SAFETY; ECONOMIC ASPECT; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; GENE; HOT FLUSH; HUMAN; KIDNEY DISEASE; LEG CRAMP; LIVER TOXICITY; META ANALYSIS (TOPIC); MUSCLE SPASM; MYALGIA; MYOSITIS; OSSIFICATION; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; UTERUS CANCER; VENOUS THROMBOEMBOLISM; ANIMAL; BIOAVAILABILITY; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; FEMALE; MALE; OSTEOPOROTIC FRACTURES;

ANIMALS; BIOLOGICAL AVAILABILITY; BONE RESORPTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; OSTEOGENESIS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; TOCOTRIENOLS;

EID: 84889030592     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990193     Document Type: Article

References (158)

1. Mori M, Nishikawa T, Masuno K, et al. Statins: candidates forpromoting bone formation via BMP-2. Oral Med Patho 2009; 14: 81-7.
2. Mundy GR. Nutritional modulators of bone remodeling duringaging. Am J Clin Nutr 2006; 83: 427S-430S.
3. Sibai T, Morgan EF, Einhorn TA. Anabolic agents and bone qual-ity. Clin Orthop Relat Res 2011; 469: 2215-24.
4. Garrett IR. Anabolic agents and the bone morphogenetic proteinpathway. Curr Top Dev Biol 2007; 78: 127-71
5. Rejnmark L, Buus NH, Vestergaard P, et al. Effects of simvastatinon bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 2004; 19: 737-44.
6. Bone HG, Kiel DP, Lindsay RS, et al. Effects of atorvastatin onbone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab 2007; 92: 4671-7.
7. Patil S, Holt G, Raby N, et al, Prospective, double blind, randomized, controlled trial of simvastatin in human fracture healing. J Orthop Res 2009; 27: 281-5.
8. Gonyeau MJ. Statins and osteoporosis: a clinical review. Pharmacotherapy 2005; 25: 228-43.
9. Sharif PS, Abdollahi M, A systematic review on the relationbetween use of statins and osteoporosis. Int J of Pharmacol 2011; 7: 180-8.
10. Cruz AC, Gruber BL. Statins and osteoporosis: can these lipid-lowering drugs also bolster bones?. Cleve Clin J Med 2002; 69: 277-88
11. Lacroix AZ, Cauley JA, Jackson R, et al. Does statin use reducerisk of fracture in postmenopausal women? Results from the Women's Health Initiative Observational Study. J Bone Min Res 2000; 15: S155.
12. Braatvedt GD, Bagg W, Gamble G, Davidson J, Reid IR. Theeffect of atorvastatin on markers of bone turnover in patients with type 2 diabetes. Bone 2004; 35: 766-70.
13. Crockett JC, Rogers MJ, Coxon FP, Hocking LJ, Helfrich MH. Bone remodelling at a glance. J Cell Sci 2011; 124: 991-8.
14. Frost HM. Osteoporoses: A Rationale for Further Definitions? Calcif Tissue Int 1998; 62: 89-94.
15. Weinstein RS, Manolagas, SC. Apoptosis and osteoporosis. Am JMed 2000; 108: 153-64.
16. Bartl R, Frisch B. Osteoporosis: Diagnosis, Prevention, Therapy, 2nd ed. Springer 2009
17. Davies JE, Hosseini, MM. Histodinamics of endosseous woundhealing. In Davies, J.E. (ed.). Bone Engineering. 1-14. Toronto: Em Squared Inc 2000.
18. Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y AcadSci 2006; 1092: 385-96.
19. Steiner E, Jergas M, Genant HK. Radiology of osteoporosis. In:Marcus E (ed) Osteoporosis. Academic, San Diego 1996.
20. Parfitt AM. Misconceptions (2): turnover is always higher in can-cellous than in cortical bone. Bone 2002; 30: 807-9.
21. Clarke B. Normal bone anatomy and physiology. Clin J Am SocNephrol 2008, 3: S131-9.
22. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, andprospects. J Clin Invest 2005; 115: 3318-25.
23. Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporoticfractures. Osteoporos Int 2004; 15: 38-42.
24. Armas LA, Recker RR. Pathophysiology of osteoporosis: newmechanistic insights. Endocrinol Metab Clin North Am 2012; 41: 475-86.
25. McNamara LM. Perspective on post-menopausal osteoporosis:establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. J R Soc Interface 2010; 7: 353-72.
26. Estai MA, Suhaimi F, Soelaiman IN, Shuid AN, Das S. Bone his-tomorphometric study of young rats following oestrogen deficiency. AJB 2011; 10: 12064-70
27. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: aninflammatory tale. J Clin Invest 2006; 116: 1186-94.
28. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construc-tion and conservation of the adult skeleton. Endocr Rev 2002; 23: 279-302.
29. Tomkinson A, Reeve J, Shaw RW, Noble BS. The death of osteo-cytes via apoptosis accompanies estrogen withdrawal in human bone. J. Clin. Endocrinol. Metab. 1997; 82: 3128-35.
30. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001; 104: 719-30.
31. Knothe Tate ML, Adamson JR, Tami, AE, Bauer TW. The osteo-cyte. Int J Biochem. Cell Biol 2004; 36: 1-8.
32. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006; 38: S4-9.
33. Kanis JA (2007) WHO Technical Report, University of Sheffield, UK: 66.
34. Rizzoli R, Reginster JY, Boonen S, et al. Adverse reactions anddrug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 2011; 89:91-104.
35. Dempster DW. Osteoporosis and the burden of osteoporosis-relatedfractures. Am J Manag Care 2011; 17: S164-S169.
36. Babbar RK, Handa AB, Lo CM, et al. Bone health of immigrantChinese women living in New York City. J Community Health.2006; 31: 7-23.
37. Barrett-Connor E, Siris ES, Wehren LE et al. Osteoporosis andfracture risk in women of different ethnic groups. J Bone Miner Res 2005; 20: 185-94.
38. Finkelstein JS, Lee M-LT, Sowers M, et al. Ethnic variation inbone density in premenopausal and early perimenopausal women: effects of anthropometric and lifestyle factors. J Clin Endocrinol Metab 2002; 87: 3057-67.
39. Morton DJ, Barrett-Connor E, Kritz-Silverstein D, et al. Bonemineral density in postmenopausal Caucasian, Filipina, and Hispanic women. Int J Epidemiol 2003; 32: 150-6.
40. Lim PS, Ong FB, Adeeb N, et al. Bone health in urban midlifeMalaysian women: risk factors and prevention. Osteoporos Int 2005; 16: 2069-79.
41. Chin KY, Ima-Nirwana S, Isa Naina M, et al. Calcaneal quantita-tive ultrasound value for middle-aged and elderly Malaysian Chinese men and its association with age and body anthropometry. J Clin Densitom 2012; 15: 86-91.
42. Chin KY, Soelaiman IN, Mohamed IN, et al. Testosterone is asso-ciated with age-related changes in bone health status, muscle strength and body composition in men. Aging Male 2012; 15: 240-5.
43. Cole ZA, Dennison EM, Cooper C. Osteoporosis epidemiologyupdate. Curr Rheumatol Rep 2008; 10: 92-6.
44. Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Howmany women have osteoporosis? JBMR Anniversary Classic. J Bone Miner Res 2005; 20: 886-92.
45. Becker DJ, Kilgore ML, Morrisey MA. The societal burden ofosteoporosis. Curr Rheumatol Rep 2010; 12: 186-91.
46. Johnell O, Kanis. An estimate of the worldwide prevalence anddisability associated with osteoporotic fractures. Osteoporos Int 2006; 17: 1726-33.
47. Lau EMC, Cooper C. The epidemiology of osteoporosis: The ori-ental perspective in a world context. Clin Orthop Relat Res 1999; 323: 65-74.
48. Gullberg B, Johnell O, Kanis JA. World-wide projections for hipfracture. Osteoporos Int 1997; 7: 407-13.
49. Harvey N, Dennison E, Cooper C. Osteoporosis: impact on healthand economics. Nat Rev Rheumatol 2010; 6: 99-105
50. Johnell O. The socioeconomic burden of fractures: today and in the21st century. Am J Med 1997; 103: S25-S26.
51. Burge RT, Dawson-Hughes B, Solomon D, et al. Incidence andeconomic burden of osteoporotic fractures in the United States, 2005-2025. J Bone Min Res 2007; 22: 465-75.
52. Lee JK and Khir ASM. The incidence of hip fracture in Malaysiansabove 50 years of age: variation in different ethnic groups. J Rheumatol 2007; 10: 300-5.
53. Colon-Emeric CS, Saag KG. Osteoporotic fractures in older adults. Best Pract Res Clin Rheumatol 2006; 20: 695-706.
54. Cummings SR, Melton JR. Epidemiology and outcomes of osteo-porotic fractures. Lancet 2002; 359: 1761-7.
55. Colon-Emeric C, Kuchibhatla M, Pieper C, et al. The contributionof hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int 2003; 14: 879-83.
56. Laugier P. An overview of bone sonometry. Int Congr 2004; 1274:23-32.
57. Chin KY, Soelaiman IN, Mohamed IN, Ibrahim S, Wan Ngah WZ.The effects of age, physical activity level, and body anthropometry on calcaneal speed of sound value in men. Arch Osteoporos 2012; 7: 135-45.
58. Chin KY, Soelaiman IN, Mohamed IN, et al. Discrepancy betweenthe quantitative ultrasound value of malaysian men and the manufacturer's reference and the impact on classification of bone health status. J Clin Densitom 2013; 16: 189-95.
59. Töyräs J, Nieminen MT, Kröger H, Jurvelin JS. Bone mineraldensity, ultrasound velocity, and broadband attenuation predict mechanical properties of trabecular bone differently. Bone 2002; 31: 503-7.
60. Tsartsalis AN, Dokos C, Kaiafa GD, et al. Statins, bone formationand osteoporosis: hope or hype? Hormones (Athens) 2012; 11: 126-39.
61. Khajuria DK, Razdan R, Mahapatra DR. Drugs for the manage-ment of osteoporosis: a review. Rev Bras Reumatol 2011; 51: 372-82.
62. Papapoulos SE. Use of biphosphonates in the management ofpostmenopausal osteoporosis. Ann N Y Acad Sci 2011; 1218: 15-32.
63. Gallagher JC, Sai AJ. Molecular biology of bone remodeling: im-plications for new therapeutic targets for osteoporosis. Maturitas 2010; 65: 301-7.
64. von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, Rubash HE, Shanbhag AS. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 2005; 26: 6941-9.
65. Xiong Y, Yang HJ, Feng J, Shi ZL, Wu LD. Effects of alendronateon the proliferation and osteogenic differentiation of MG-63 cells. J Int Med Res 2009; 37: 407-16.
66. Koch FP, Merkel C, Al-Nawas B, et al. Zoledronate, ibandronateand clodronate enhance osteoblast differentiation in a dose dependent manner-a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2. J Craniomaxillofac Surg. 2011; 39: 562-9.
67. Migliaccio S, Brama M, and Spera G. The differential effects ofbisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis. Clin Interv Aging 2007; 2: 55-64.
68. Jilka RL, O'Brien CA, Bartell SM, Weinstein RS, Manolagas SC. Continuous Elevation of PTH Increases the Number of Osteoblasts via Both Osteoclast-Dependent and-Independent Mechanisms. J Bone Miner Res 2010; 25: 2427-37.
69. Stagnitti MN. Trends in Statins Utilization and Expenditures for theU.S. Civilian Noninstitutionalized Population, 2000 and 2005. Statistical Brief #205. May 2008. Agency for Healthcare Research and Quality, Rockville, MD. http://www.meps.ahrq.gov/mepsweb/data_files/publications/st205/stat205.pdf
70. Mundy GR. Statins and their potential for osteoporosis. Bone 2001;29: 495-7.
71. Gotto AM. Statins: Powerful drugs for lowering cholesterol. Circu-lation 2002; 105: 1514-6.
72. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharma-col Toxicol 2005; 45: 89-118.
73. Horiuchi N, Maeda T. Statins and bone metabolism. Oral Dis 2006;12: 85-10.
74. Tandon V, Bano G, Khajuria V, Parihar A, Gupta S. Pleiotropiceffects of statins. Indian J Pharmacol 2005; 37: 77-85.
75. Mihos CG, Santana O. Pleiotropic effects of the HMG-CoA reduc-tase inhibitors. Int J Gen Med 2011; 4: 261-71.
76. Pella D, Rybar R, Mechirova V. Pleiotropic Effects of Statins. ActaCardiol Sin 2005; 21: 190-8.
77. Warburton DE, Nicol CW, Gatto SN, Bredin SS. Cardiovasculardisease and osteoporosis: Balancing risk management. Vasc Health Risk Manag 2007; 3: 673-89.
78. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and strokestatistics-2011 update: A report from the american heart association. Circulation 2011; 123: e18-e209.
79. Kendrick J, Shlipak MG, Targher G, et al. Effect of lovastatin onprimary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis 2010; 55: 42-49.
80. Taylor F, Ward K, Moore TH, et al. Statins for the primary preven-tion of cardiovascular disease. Cochrane Database Syst Rev 2011; 1: CD004816.
81. Tanko LB, Christiansen C, Cox DA, et al. Relationship betweenosteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005; 20: 1912-20.
82. Ruan F, Zheng Q, Wang J. Mechanisms of bone anabolism regu-lated by statins. Biosci Rep 2012; 32: 511-9.
83. Das UN. Nitric oxide as the mediator of the antiosteoporotic ac-tions of estrogen, statins, and essential fatty acids. Exp Biol Med (Maywood) 2002; 227: 88-93.
84. Garrett IR, Mundy GR. The role of statins as potential targets forbone formation. Arthritis Res 2002; 4: 237-40.
85. Kotyla P. The role of 3-hydroxy-3-methylglutaryl coenzyme areductase inhibitors (statins) in modern rheumatology. Ther Adv Musculoskelet Dis 2010; 2: 257-69.
86. Grasser WA, Baumann AP, Petras SF, et al. Regulation of osteo-clast differentiation by statins. J Musculoskelet Neuronal Interact 2003; 3: 53-62.
87. Staal A, Frith JC, French MH, et al. The ability of statins to inhibitbone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 2003; 18: 88-96.
88. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formationin vitro and in rodents by statins. Science 1999; 286: 1946-9.
89. Maritz FJ, Conradie MM, Hulley PA, et al. Effect of statins onbone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 2001; 21: 1636-41.
90. Oxlund H, Dalstra M, Andreassen TT. Statin given perorally toadult rats increases cancellous bone mass and compressive strength. Calcif Tissue Int 2001; 69: 299-304.
91. Ho ML, Chen YH, Liao HJ, Chen CH, Hung SH, Lee MJ, Fu YC, Wang YH, Wang GJ, Chang JK. Simvastatin increases osteoblasts and osteogenic proteins in ovariectomized rats. Eur J Clin Invest 2009; 39: 296-303.
92. Skoglund B, Forslund C, Aspenberg P. Simvastatin improvesfracture healing in mice. J Bone Miner Res 2002; 17: 2004-8.
93. Yao W., Farmer R., Cooper R., et al. Simvastatin did not preventnor restore ovariectomy-induced bone loss in adult rats, J Musculoskelet Neuronal Interact 2006; 6: 277-83.
94. Abdul-Majeed S, Mohamed N, and Soelaiman IN. Effects oftocotrienol and lovastatin combination on osteoblast and osteoclast activity in estrogen-deficient osteoporosis. Evid Based Complement Alternat Med 2012; 2012: 960742.
95. Gutierrez GE, Edwards JR, Garrett IR, et al. Transdermal lovas-tatin enhances fracture repair in rats. J Bone Miner Res 2008; 23: 1722-30.
96. Jadhav SB, Narayana Murthy PS, Singh MM, Jain GK. Distribu-tion of lovastatin to bone and its effect on bone turnover in rats. J Pharm Pharmacol 2006; 58: 1451-8.
97. Bauer DC, Mundy GR, Jamal SA, et al. Use of statins and fracture:results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004; 164:146-52.
98. Uzzan B, Cohen R, Nicolas P, et al. Effects of statins on bonemineral density: a meta-analysis of clinical studies. Bone 2007; 40: 1581-7.
99. Yue J, Zhang X, Dong B, Yang M. Statins and bone health inpostmenopausal women: a systematic review of randomized controlled trials. Menopause 2010; 17: 1071-9.
100. Toh S, Hernández-Díaz S. Statins and fracture risk. A systematicreview. Pharmacoepidemiol Drug Saf 2007; 16: 627-40.
101. Hatzigeorgiou C, Jackson JL. Hydroxymethylglutaryl-coenzyme Areductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int 2005; 16: 990-8.
102. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance forthe pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19: 26-37.
103. Golomb BA, Evans MA. Statin adverse effects: a review of theliterature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008; 8: 373-418.
104. Escobar C, Echarri R, Barrios V. Relative safety profiles of highdose statin regimens. Vasc Health Risk Manag. 2008; 4: 525-533.
105. Gillett RG, Norrell A. Considerations for safe use of statins: liverenzyme abnormalities and muscle toxicity. Am Fam Physician 2011; 83: 711-6.
106. Law M, Rudnicka AR. Statin safety: a systematic review. Am JCardiol 2006; 97: 52C-60C.
107. Armitage J. The safety of statins in clinical practice. Lancet 2007;370(9601): 1781-90.
108. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhab-domyolysis. N Engl J Med 2002; 346: 539-40.
109. Stancu C, Sima A. Statins: mechanism of action and effects. J CellMol Med. 2001; 5: 378-87.
110. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: acommon dilemma not reflected in clinical trials. Cleve Clin J Med2011; 78: 393-403.
111. Zingg, J.M. Vitamin E: An overview of major research directions. Mol. Aspects Med 2007; 28: 400-22.
112. Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond toco-pherols. Life Sci. 2006; 78: 2088-98.
113. Sen CK, Khanna S, Roy S. Tocotrienols in health and disease: theother half of the natural vitamin E family. Mol Aspects Med 2007; 28: 692-728.
114. Aggarwal BB, Sundaram C, Prasad S, Kannappan R. Tocotrienols,the vitamin E of the 21st century: its potential against cancer and other chronic diseases. Biochem Pharmacol 2010; 80(11): 1613-31.
115. Frega N, Mozzon M, Bocci F. Identification and estimation oftocotrienols in the annatto lipid fraction by gas chromatographymass spectrometry. J Am Oil Chem Soc 1998; 75: 1723-7.
116. Song BL, DeBose-Boyd RA. Insig-dependent ubiquitination anddegradation of 3-hydroxy-3-methylglutaryl coenzyme a reductase stimulated by-and-tocotrienols. J Biol Chem 2006; 281: 25054-61.
117. Qureshi AA, Peterson DM, Hasler-Rapacz JO, Rapacz J. Noveltocotrienols of rice bran suppress cholesterogenesis in hereditary hypercholesterolemic swine. J Nutr 2001; 131: 223-30.
118. Chen CW, Cheng HH. A rice bran oil diet increases LDL-receptorand HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes. J Nutr 2006; 136: 1472-6.
119. Poveda E, Ayala P, Milena R, et al. Effects of vegetal oil supple-mentation on the lipid profile of Wistar rats. Biomedica 2005; 25: 101-9.
120. Budin SB, Othman F, Louis SR, Bakar MA, Das S, Mohamed J. The effects of palm oil tocotrienolrich fraction supplementation on biochemical parameters, oxidative stress and the vascular wall of streptozotocin-induced diabetic rats. Clinics (Sao Paulo) 2009; 64: 235-44.
121. Qureshi AA, Sami SA, Salser WA, Khan FA. Dose-dependentsuppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans. Atherosclerosis 2002;161: 199-207.
122. Qureshi AA, Sami SA, Salser WA, Khan FA. Synergistic effect oftocotrienol-rich fraction (TRF(25)) of rice bran and lovastatin on lipid parameters in hypercholesterolemic humans. J Nutr Biochem 2001; 12: 318-29.
123. Norazlina M, Ima Nirwana S, Khalid BAK. Effects of palm vita-min E, vitamin D and calcium supplementation on bone metabolism in vitamin E deficient rats. Medical Journal of Islamic Academy of Science 1999; 12: 89-96.
124. Norazlina M, Rita LHL, Ima-Nirwana S. The effects of vitamin Eor calcium supplementation on bone mineral composition in vitamin E deficient rats. Malaysian Journal of Biochemistry and Molecular Biology 2002; 7: 1-5.
125. Norazlina M, Ima-Nirwana S, Abul Gapor MT, Abdul Kadir Khalid B. Tocotrienols are needed for normal bone calcification in growing female rats. Asia Pac J Clin Nutr 2002; 11: 194-9.
126. Norazlina M, Chua CW, Ima-Nirwana S. Vitamin E deficiencyreduced lumbar bone calcium content in female rats. Med J Malaysia 2004; 59: 623-30.
127. Ima-Nirwana S, Fakhrurazi H. Palm vitamin E protects boneagainst dexamethasone-induced osteoporosis in male rats. Med J Malaysia 2002; 57: 136-44.
128. Ima-Nirwana S, Kiftiah A, Zainal AG, et al. Palm vitamin E pre-vents osteoporosis in orchidectomized growing male rats. Nat Prod Sci 2000; 6: 155-60.
129. Norazlina M, Ima-Nirwana S, Gapor MT, Khalid BA. Palm vitamin E is comparable to alpha-tocopherol in maintaining bone mineral density in ovariectomised female rats. Exp Clin Endocrinol Diabetes 2000; 108: 305-10.
130. Norazlina M, Ng FW, Ima-Nirwana S.-Tocotrienol is required fornormal vitamin D metabolism in female rats. Indian J Pharmacol 2005; 37: 309-14.
131. Ima-Nirwana S, Suhaniza S. Effects of tocopherols and tocotrienolson body composition and bone calcium content in adrenalectomized rats replaced with dexamethasone. J Med Food 2004; 7: 45-51.
132. Hermizi H, Faizah O, Ima-Nirwana S, et al. Nicotine impairedbone histomorphometric parameters and bone remodeling biomarkers in Sprague-Dawley male rats. Annals of Microscopy 2007; 7: 10-24.
133. Hapidin H, Othman F, Soelaiman IN, et al. Negative effects ofnicotine on bone-resorbing cytokines and bone histomorphometric parameters in male rats. J Bone Miner Metab 2007; 25: 93-98.
134. Norazlina M, Lee PL, Lukman HI, Nazrun AS, Ima-Nirwana S. Effects of vitamin E supplementation on bone metabolism in nicotine-treated rats. Singapore Medical Journal 2007; 48: 195-9.
135. Norazlina M, Hermizi H, Faizah O, Ima-Nirwana S. Vitamin Ereversed nicotine-induced toxic effects on bone biochemical markers in male rats. Arch Med Sci 2010; 6: 505-12.
136. Hapidin H, Othman F, Soelaiman IN, Shuid AN, Mohamed N. Effects of nicotine administration and nicotine cessation on bone histomorphometry and bone biomarkers in Sprague-Dawley male rats. Calcif Tissue Int 2011; 88: 41-7.
137. Hermizi H, Faizah O, Ima-Nirwana S, Ahmad Nazrun S, Norazlina M. Beneficial effects of tocotrienol and tocopherol on bone histomorphometric parameters in Sprague-Dawley male rats after nicotine cessation. Calcif Tissue Int 2009; 84: 65-74.
138. Abukhadir SS, Mohamed N, Makpol S, Muhammad N. Effects ofpalm vitamin e on bone-formation-related gene expression in nicotine-treated rats. Evid Based Complement Alternat Med 2012; 2012: 656025.
139. Nazrun AS, Luke DA, Khalid BAK, Ima-Nirwana S. Vitamin Eprotects from free-radical damage on femur of rats treated with ferric nitrilotriacetate. Curr Top Pharmacol 2005; 9: 107-15.
140. Ahmad NS, Khalid BAK, Luke DA, Ima-Nirwana S. Tocotrienoloffers better protection than tocopherol from free radical-induced damage of rat bone. Clin Exp Pharmacol Physiol 2005; 32: 761-770.
141. Maniam S, Mohamed N, Shuid AN, Soelaiman IN. Palm to-cotrienol exerted better antioxidant activities in bone than alphatocopherol. Basic Clin Pharmacol Toxicol 2008; 103: 55-60.
142. Nazrun A, Khairunnur A, Norliza M, Norazlina M, Ima-Nirwana S. Effects of palm tocotrienol on oxidative stress and bone strength in ovariectomised rats. Medicine and Health. 2008; 3: 83-90.
143. Shuid AN, Mehat Z, Mohamed N, Muhammad N, Soelaiman IN. Vitamin E exhibits bone anabolic actions in normal male rats. J Bone Miner Metab 2010; 28: 149-56.
144. Mehat MZ, Shuid AN, Mohamed N, Muhammad N, Soelaiman IN. Beneficial effects of vitamin E isomer supplementation on static and dynamic bone histomorphometry parameters in normal male rats. J Bone Miner Metab 2010; 28: 503-9.
145. Watts NB, Bilezikian JP, Camacho PM, et al. American Associa-tion of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 2010; 3: 1-37.
146. Aktifanus AT, Shuid AN, Rashid NHA, et al. Comparison of theeffects of tocotrienol and estrogen on the bone markers and dynamic changes in postmenopausal osteoporosis rat model. Asian J Anim Vet Adv 2012; 7: 225-34.
147. Soelaiman IN, Ming W, Abu Bakar R, et al. Palm tocotrienol sup-plementation enhanced bone formation in oestrogen-deficient rats. Int J Endocrinol 2012; 2012: 532862.
148. Muhammad N, Luke DA, Shuid AN, Mohamed N, Soelaiman IN. Two different isomers of vitamin e prevent bone loss in postmenopausal osteoporosis rat model. Evid Based Complement Alternat Med 2012; 2012: 161527.
149. Mohamad S, Shuid AN, Mokhtar SA, Abdullah S, Soelaiman IN.Tocotrienol supplementation improves late-phase fracture healing compared to alpha-tocopherol in a rat model of postmenopausal osteoporosis: a biomechanical evaluation. Evid Based Complement Alternat Med 2012; 2012: 372-878.
150. Mo H, Yeganehjoo H, Shah A, et al. Mevalonate-suppressive die-tary isoprenoids for bone health. J Nutr Biochem 2012; 23: 1543-51.
151. Chin KY, Ima-Nirwana S. Vitamin E as an Antiosteoporotic Agentvia Receptor Activator of Nuclear Factor Kappa-B Ligand Signaling Disruption: Current Evidence and Other Potential Research Areas. Evid Based Complement Alternat Med 2012; 2012: 747020.
152. Yu SG, Thomas AM, Gapor A, et al. Dose-response impact ofvarious tocotrienols on serum lipid parameters in 5-week-old female chickens. Lipids 2006; 41: 453-61.
153. Nakamura H, Furukawa F, Nishikawa A, Miyauchi M, Son HY, Imazawa T, Hirose M. Oral toxicity of a tocotrienol preparation in rats. Food Chem Toxicol 2001; 39: 799-805.
154. Ima-Nirwana S, Nurshazwani Y, Nazrun AS, Norliza M, Norazlina M Subacute and subchronic toxicity studies of palm vitamin E in mice. J Pharmacol Toxicol 2011; 6: 166-73.
155. McAnally JA, Gupta J, Sodhani S, Bravo L, Mo H. Tocotrienolspotentiate lovastatin-mediated growth suppression in vitro and in vivo. Exp Biol Med (Maywood) 2007; 232: 523-31.
156. Wali VB, Sylvester PW. Synergistic antiproliferative effects of-tocotrienol and statin treatment on mammary tumor cells. Lipids2007; 42: 1113-23.
157. Hussein D, Mo H. D-Tocotrienol-mediated suppression of the proliferation of human PANC-1, MIA PaCa2 and BxPC-3 pancreatic carcinoma cells. Pancreas 2009; 38: e124-36.
158. Sylvester PW. Synergistic anticancer effects of combined-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment. Genes Nutr 2012; 7: 63-74.